Perkins Capital Management Inc. Increases Holdings in Biodesix, Inc. (NASDAQ:BDSX)

Perkins Capital Management Inc. grew its stake in Biodesix, Inc. (NASDAQ:BDSX) by 46.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,060,211 shares of the company’s stock after acquiring an additional 335,429 shares during the quarter. Biodesix accounts for 1.4% of Perkins Capital Management Inc.’s portfolio, making the stock its 23rd biggest holding. Perkins Capital Management Inc. owned about 0.73% of Biodesix worth $1,622,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently modified their holdings of BDSX. Barclays PLC increased its stake in Biodesix by 1,140.5% during the 3rd quarter. Barclays PLC now owns 23,036 shares of the company’s stock valued at $41,000 after purchasing an additional 21,179 shares in the last quarter. HighTower Advisors LLC increased its position in shares of Biodesix by 17.1% during the fourth quarter. HighTower Advisors LLC now owns 153,934 shares of the company’s stock valued at $236,000 after acquiring an additional 22,500 shares in the last quarter. Landscape Capital Management L.L.C. purchased a new position in Biodesix in the 3rd quarter worth approximately $262,000. Stephens Inc. AR bought a new position in Biodesix in the 4th quarter valued at approximately $303,000. Finally, Geode Capital Management LLC boosted its stake in Biodesix by 50.7% during the 3rd quarter. Geode Capital Management LLC now owns 804,576 shares of the company’s stock valued at $1,433,000 after purchasing an additional 270,724 shares during the last quarter. 20.96% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Biodesix

In related news, CEO Scott Hutton sold 83,660 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total transaction of $76,967.20. Following the completion of the sale, the chief executive officer now directly owns 701,947 shares in the company, valued at approximately $645,791.24. The trade was a 10.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 128,702 shares of company stock worth $118,406 in the last three months. 69.20% of the stock is currently owned by company insiders.

Biodesix Stock Up 3.8 %

Shares of Biodesix stock opened at $0.85 on Monday. Biodesix, Inc. has a twelve month low of $0.64 and a twelve month high of $2.04. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 1.30. The company’s 50 day moving average is $0.93 and its 200 day moving average is $1.32. The company has a market cap of $123.54 million, a price-to-earnings ratio of -2.17 and a beta of 1.10.

Biodesix (NASDAQ:BDSX) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01. The firm had revenue of $20.43 million for the quarter, compared to analysts’ expectations of $19.92 million. Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%. Research analysts anticipate that Biodesix, Inc. will post -0.35 EPS for the current year.

Analysts Set New Price Targets

Separately, William Blair reaffirmed an “outperform” rating on shares of Biodesix in a report on Tuesday, March 4th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $2.95.

Biodesix Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.